Bone marrow niche-inspired, multiphase expansion of megakaryocytic progenitors with high polyploidization potential.

Swapna Panuganti, Eleftherios T Papoutsakis, William M Miller
Author Information
  1. Swapna Panuganti: Department of Chemical and Biological Engineering, Northwestern University, Evanston, Illinois 60208, USA.

Abstract

BACKGROUND AIMS: Megakaryopoiesis encompasses hematopoietic stem and progenitor cell (HSPC) commitment to the megakaryocytic cell (Mk) lineage, expansion of Mk progenitors and mature Mks, polyploidization and platelet release. pH and pO2 increase from the endosteum to sinuses, and different cytokines are important for various stages of differentiation. We hypothesized that mimicking the changing conditions during Mk differentiation in the bone marrow would facilitate expansion of progenitors that could generate many high-ploidy Mks.
METHODS: CD34+ HSPCs were cultured at pH 7.2 and 5% O2 with stem cell factor (SCF), thrombopoietin (Tpo) and all combinations of Interleukin (IL)-3, IL-6, IL-11 and Flt-3 ligand to promote Mk progenitor expansion. Cells cultured with selected cytokines were shifted to pH 7.4 and 20% O2 to generate mature Mks, and treated with nicotinamide (NIC) to enhance polyploidization.
RESULTS: Using Tpo + SCF + IL-3 + IL-11, we obtained 3.5 CD34+ CD41+ Mk progenitors per input HSPC, while increasing purity from 1% to 17%. Cytokine cocktails with IL-3 yielded more progenitors and mature Mks, although the purities were lower. Mk production was much greater at higher pH and pO2. Although fewer progenitors were present, shifting to 20% O2 /pH 7.4 at day 5 (versus days 7 or 9) yielded the greatest mature Mk production, 14 per input HSPC. NIC more than doubled the percentage of high-ploidy Mks to 40%.
CONCLUSIONS: We obtained extensive Mk progenitor expansion, while ensuring that the progenitors could produce high-ploidy Mks. We anticipate that subsequent optimization of cytokines for mature Mk production and delayed NIC addition will greatly increase high-ploidy Mk production.

References

  1. Nat Rev Immunol. 2006 Feb;6(2):93-106 [PMID: 16491134]
  2. J Thromb Haemost. 2008 Nov;6(11):1900-7 [PMID: 18752571]
  3. Br J Haematol. 1998 Nov;103(2):317-25 [PMID: 9827900]
  4. Exp Hematol. 2005 Oct;33(10):1182-91 [PMID: 16219540]
  5. Br J Haematol. 2006 Nov;135(4):554-66 [PMID: 17054670]
  6. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004269 [PMID: 15495093]
  7. Blood. 2002 Feb 1;99(3):888-97 [PMID: 11806991]
  8. Br J Haematol. 2004 Aug;126(4):536-45 [PMID: 15287947]
  9. J Hematother Stem Cell Res. 2001 Feb;10(1):193-200 [PMID: 11276373]
  10. Blood. 1996 Aug 15;88(4):1284-96 [PMID: 8695846]
  11. Exp Hematol. 2009 Nov;37(11):1340-1352.e3 [PMID: 19715739]
  12. Blood. 2008 Jun 1;111(11):5298-306 [PMID: 18388179]
  13. Leukemia. 2008 Jan;22(1):203-8 [PMID: 17943170]
  14. Platelets. 2001 Sep;12(6):325-32 [PMID: 11672471]
  15. Stem Cells Dev. 2004 Aug;13(4):362-71 [PMID: 15345130]
  16. Exp Hematol. 2003 Apr;31(4):324-30 [PMID: 12691920]
  17. Bone Marrow Transplant. 1998 Jun;21 Suppl 3:S48-53 [PMID: 9712494]
  18. Blood. 1998 May 15;91(10):3711-23 [PMID: 9573008]
  19. J Interferon Cytokine Res. 2006 Feb;26(2):76-82 [PMID: 16487027]
  20. Stem Cells. 1997;15(1):18-32 [PMID: 9007219]
  21. Transfus Med. 2007 Apr;17(2):119-27 [PMID: 17430468]
  22. Semin Hematol. 2007 Jul;44(3):166-82 [PMID: 17631181]
  23. Stem Cells. 2002;20(4):320-8 [PMID: 12110701]
  24. Semin Hematol. 2009 Jan;46(1 Suppl 2):S26-32 [PMID: 19245931]
  25. Blood. 1998 Jun 1;91(11):4118-26 [PMID: 9596657]
  26. Biotechnol Prog. 1998 May-Jun;14(3):466-72 [PMID: 9622528]
  27. Exp Hematol. 2000 Sep;28(9):1054-61 [PMID: 11008018]
  28. J Thromb Haemost. 2007 Jul;5 Suppl 1:318-27 [PMID: 17635743]
  29. Exp Hematol. 2008 Oct;36(10):1337-42 [PMID: 18619724]
  30. Exp Hematol. 2005 Dec;33(12):1537-43 [PMID: 16338497]
  31. Blood. 1997 Apr 15;89(8):2679-88 [PMID: 9108385]
  32. Biotechnology (N Y). 1994 Sep;12(9):909-14 [PMID: 7521647]
  33. Curr Opin Hematol. 2006 Sep;13(5):323-30 [PMID: 16888436]
  34. Br J Haematol. 2000 Dec;111(3):879-89 [PMID: 11122151]
  35. Blood. 2001 Mar 15;97(6):1635-43 [PMID: 11238102]
  36. Lancet. 2007 Aug 4;370(9585):427-38 [PMID: 17679020]
  37. Stem Cells. 1997;15(3):198-206 [PMID: 9170211]
  38. Br J Haematol. 2000 Jun;109(4):776-84 [PMID: 10929029]
  39. Bone Marrow Transplant. 2004 Dec;34(12):1089-93 [PMID: 15489877]
  40. J Hematother Stem Cell Res. 2000 Dec;9(6):913-21 [PMID: 11177605]
  41. Haematologica. 2004 May;89(5):630-1 [PMID: 15136238]
  42. J Hematother Stem Cell Res. 2003 Apr;12(2):179-88 [PMID: 12804177]
  43. Exp Hematol. 2000 Mar;28(3):267-75 [PMID: 10720691]
  44. Exp Hematol. 2000 Mar;28(3):335-46 [PMID: 10720698]
  45. Exp Hematol. 1997 Oct;25(11):1187-94 [PMID: 9328456]
  46. Stem Cells. 2003;21(1):33-40 [PMID: 12529549]
  47. Biotechnol Bioeng. 1998 Sep 5;59(5):534-43 [PMID: 10099369]
  48. Cytotechnology. 1998 Nov;28(1-3):127-38 [PMID: 19003414]
  49. Exp Hematol. 1998 Aug;26(9):835-43 [PMID: 9694504]
  50. Biophys J. 2001 Aug;81(2):685-96 [PMID: 11463617]
  51. Ann Hematol. 2000 Jan;79(1):13-9 [PMID: 10663616]
  52. J Immunol Methods. 2008 Mar 20;332(1-2):82-91 [PMID: 18234208]
  53. Blood. 2005 Apr 1;105(7):2631-9 [PMID: 15585658]
  54. Stem Cells Dev. 2005 Aug;14(4):415-24 [PMID: 16137231]

Grants

  1. T32 GM008449/NIGMS NIH HHS
  2. T32 GM 008449/NIGMS NIH HHS

MeSH Term

Antigens, CD34
Blood Platelets
Bone Marrow
Cell Culture Techniques
Cell Differentiation
Cell Lineage
Cell Proliferation
Cells, Cultured
Humans
Interleukins
Megakaryocyte Progenitor Cells
Niacinamide
Platelet Transfusion
Polyploidy
Stem Cell Factor
Stem Cell Niche
Thrombocytopenia
Thrombopoietin

Chemicals

Antigens, CD34
Interleukins
Stem Cell Factor
Niacinamide
Thrombopoietin

Word Cloud

Created with Highcharts 10.0.0MkprogenitorsMksexpansionmaturepHhigh-ploidy7productionprogenitorcellHSPCpolyploidizationcytokinesO2NIC+stemmegakaryocyticpO2increasedifferentiationmarrowgenerateCD34+culturedSCFTpoIL-11420%IL-3obtained5perinputyieldedBACKGROUNDAIMS:MegakaryopoiesisencompasseshematopoieticcommitmentlineageplateletreleaseendosteumsinusesdifferentimportantvariousstageshypothesizedmimickingchangingconditionsbonefacilitatemanyMETHODS:HSPCs25%factorthrombopoietincombinationsInterleukinIL-3IL-6Flt-3ligandpromoteCellsselectedshiftedtreatednicotinamideenhanceRESULTS:Using3CD41+increasingpurity1%17%CytokinecocktailsalthoughpuritieslowermuchgreaterhigherAlthoughfewerpresentshifting/pHdayversusdays9greatest14doubledpercentage40%CONCLUSIONS:extensiveensuringproduceanticipatesubsequentoptimizationdelayedadditionwillgreatlyBoneniche-inspiredmultiphasehighpotential

Similar Articles

Cited By